Mortality risk with dual antiplatelet therapy? Robert W Yeh, Sammy Elmariah, Gheorghe Doros, Dean J Kereiakes, Laura Mauri The Lancet Volume 386, Issue 10003, Pages 1533-1534 (October 2015) DOI: 10.1016/S0140-6736(15)00486-9 Copyright © 2015 Elsevier Ltd Terms and Conditions
Figure Extended duration dual antiplatelet therapy and all-cause mortality Updated comprehensive meta-analysis of trials assessing extended duration dual antiplatelet therapy (DAPT) in cardiovascular and cerebrovascular disease, showing no significant association between extended therapy and all-cause mortality. Data are n (events). *The six randomised clinical trials excluded by Palmerini and colleagues' study.2 The Lancet 2015 386, 1533-1534DOI: (10.1016/S0140-6736(15)00486-9) Copyright © 2015 Elsevier Ltd Terms and Conditions